日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

由于 p53 功能障碍和基因组加倍导致染色体不稳定性,靶向治疗的效果参差不齐

Sebastijan Hobor #, Maise Al Bakir #, Crispin T Hiley #, Marcin Skrzypski #, Alexander M Frankell, Bjorn Bakker, Thomas B K Watkins, Aleksandra Markovets, Jonathan R Dry, Andrew P Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

基于知识图谱的推荐框架可识别 EGFR 突变型非小细胞肺癌的耐药驱动因素

Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michaël Ughetto, Matthew J Martin, Hannah Thorpe, Aurelie Bornot, Paul D Smith, Ben Sidders, Jonathan R Dry, Miika Ahdesmäki, Ultan McDermott, Eliseo Papa, Krishna C Bulusu

A pan-cancer organoid platform for precision medicine

用于精准医疗的泛癌症类器官平台

Brian M Larsen, Madhavi Kannan, Lee F Langer, Benjamin D Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E Drummond, Jonathan R Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A Krantz, Brandon Mapes, Kelly E McKinnon, Jessica Metti, Jason F Perera, Tim A Rand, Veronica Sanchez-Freire

BloodPAC Data Commons for Liquid Biopsy Data

BloodPAC 液体活检数据共享

Robert L Grossman, Jonathan R Dry, Sean E Hanlon, Donald J Johann, Anand Kolatkar, Jerry S H Lee, Christopher Meyer, Lea Salvatore, Walt Wells, Lauren Leiman

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

MEK1/2 抑制剂停药可逆转由 BRAFV600E 扩增驱动的获得性耐药性,而 KRASG13D 扩增则促进 EMT 化学耐药性

Matthew J Sale, Kathryn Balmanno, Jayeta Saxena, Eiko Ozono, Katarzyna Wojdyla, Rebecca E McIntyre, Rebecca Gilley, Anna Woroniuk, Karen D Howarth, Gareth Hughes, Jonathan R Dry, Mark J Arends, Pilar Caro, David Oxley, Susan Ashton, David J Adams, Julio Saez-Rodriguez, Paul D Smith, Simon J Cook1

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

针对黑色素瘤的 MCL1 偏向释放了 BRAF 和 ERK1/2 通路抑制剂的凋亡潜力

Matthew J Sale, Emma Minihane, Noel R Monks, Rebecca Gilley, Frances M Richards, Kevin P Schifferli, Courtney L Andersen, Emma J Davies, Mario Aladren Vicente, Eiko Ozono, Aleksandra Markovets, Jonathan R Dry, Lisa Drew, Vikki Flemington, Theresa Proia, Duncan I Jodrell, Paul D Smith, Simon J Cook

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

识别 AZD4547 抑制 FGFR 后的药效学转录生物标志物

Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret Veldman-Jones, Joanne Wilson, Barry R Davies, Jonathan R Dry, Elaine Kilgour, Paul D Smith

RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib

RNA-Seq 区分使用 VEGFR 酪氨酸激酶抑制剂 Cediranib 治疗人类肿瘤异种移植引起的肿瘤和宿主 mRNA 表达变化

James R Bradford, Matthew Farren, Steve J Powell, Sarah Runswick, Susie L Weston, Helen Brown, Oona Delpuech, Mark Wappett, Neil R Smith, T Hedley Carr, Jonathan R Dry, Neil J Gibson, Simon T Barry